GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Quick Ratio

Fusion Antibodies (LSE:FAB) Quick Ratio : 2.32 (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Fusion Antibodies's quick ratio for the quarter that ended in Sep. 2023 was 2.32.

Fusion Antibodies has a quick ratio of 2.32. It generally indicates good short-term financial strength.

The historical rank and industry rank for Fusion Antibodies's Quick Ratio or its related term are showing as below:

LSE:FAB' s Quick Ratio Range Over the Past 10 Years
Min: 1.31   Med: 3.06   Max: 9.52
Current: 2.32

During the past 9 years, Fusion Antibodies's highest Quick Ratio was 9.52. The lowest was 1.31. And the median was 3.06.

LSE:FAB's Quick Ratio is ranked worse than
62.23% of 1546 companies
in the Biotechnology industry
Industry Median: 3.595 vs LSE:FAB: 2.32

Fusion Antibodies Quick Ratio Historical Data

The historical data trend for Fusion Antibodies's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Quick Ratio Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only 3.85 2.49 4.24 3.06 1.31

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.57 3.06 2.36 1.31 2.32

Competitive Comparison of Fusion Antibodies's Quick Ratio

For the Biotechnology subindustry, Fusion Antibodies's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Antibodies's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Quick Ratio falls into.



Fusion Antibodies Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Fusion Antibodies's Quick Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Quick Ratio (A: Mar. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.687-0.538)/0.879
=1.31

Fusion Antibodies's Quick Ratio for the quarter that ended in Sep. 2023 is calculated as

Quick Ratio (Q: Sep. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.808-0.524)/0.554
=2.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusion Antibodies  (LSE:FAB) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Fusion Antibodies Quick Ratio Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies (LSE:FAB) Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022